Free Trial

Absci (NASDAQ:ABSI) Stock Falls 9.6% Following Analyst Downgrade

Absci logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Absci shares fell 9.6% after Guggenheim cut its price target from $15 to $14, while maintaining a Buy rating; the stock closed at $7.641.
  • Analyst sentiment remains broadly positive: 11 analysts rate Absci Buy and one rates it Sell, with a consensus “Moderate Buy” rating and average target of $14.90.
  • In its latest quarter, Absci reported a loss of $0.19 per share, in line with estimates, while revenue of $0.30 million came in below analysts’ $0.66 million forecast.
  • Interested in Absci? Here are five stocks we like better.

Shares of Absci Corporation (NASDAQ:ABSI - Get Free Report) fell 9.6% on Monday after Guggenheim lowered their price target on the stock from $15.00 to $14.00. Guggenheim currently has a buy rating on the stock. Absci traded as low as $7.29 and last traded at $7.6410. 996,995 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 4,304,985 shares. The stock had previously closed at $8.45.

A number of other equities research analysts have also issued reports on ABSI. HC Wainwright reiterated a "buy" rating on shares of Absci in a report on Tuesday, October 20th. Weiss Ratings restated a "sell (d-)" rating on shares of Absci in a research note on Thursday, October 15th. Needham & Company LLC boosted their price target on shares of Absci from $11.00 to $15.00 and gave the stock a "buy" rating in a research note on Thursday. JPMorgan Chase & Co. upped their price objective on Absci from $14.00 to $15.00 and gave the stock an "overweight" rating in a research report on Monday, October 12th. Finally, Jefferies Financial Group started coverage on Absci in a research note on Thursday, October 29th. They issued a "buy" rating and a $14.00 price objective on the stock. Eleven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $14.90.

Get Our Latest Stock Report on Absci

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Parkman Healthcare Partners LLC purchased a new stake in Absci during the second quarter worth $10,366,000. Siren L.L.C. acquired a new stake in Absci in the first quarter valued at $5,400,000. Bank of America Corp DE acquired a new stake in Absci in the second quarter valued at $6,560,000. Deutsche Bank AG purchased a new position in shares of Absci in the second quarter valued at $1,591,000. Finally, Artia Global Partners LP purchased a new position in shares of Absci in the second quarter valued at $5,383,000. Institutional investors and hedge funds own 52.05% of the company's stock.

Absci Price Performance

The firm has a market cap of $1.33 billion, a PE ratio of -9.86 and a beta of 2.22. The business has a 50-day moving average price of $9.65 and a two-hundred day moving average price of $6.81.

Absci (NASDAQ:ABSI - Get Free Report) last released its quarterly earnings data on Thursday, November 12th. The company reported ($0.19) EPS for the quarter, hitting the consensus estimate of ($0.19). The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.66 million. Absci had a negative net margin of 8,451.31% and a negative return on equity of 61.60%. Equities analysts expect that Absci Corporation will post -0.76 earnings per share for the current fiscal year.

About Absci

(Get Free Report)

Absci Corporation is a biotechnology company that uses artificial intelligence and laboratory research to discover and develop biologic drugs. Its platform combines generative AI with experimental testing to design and evaluate potential drug candidates, including antibodies and other protein-based medicines. The company also works with pharmaceutical and biotechnology partners on drug discovery programs and advances its own pipeline of potential therapies. Its approach is intended to connect computational design with laboratory validation, helping assess whether designed molecules have useful properties.

Featured Stories

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Absci Right Now?

Before you consider Absci, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Absci wasn't on the list.

While Absci currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines